Effects of low-dose warfarin and regional chemotherapy on survival in patients with pancreatic carcinoma.
OBJECTIVE
To report the effect of regional combination chemotherapy in a cohort of patients with inoperable pancreatic carcinoma treated with or without low-dose warfarin.


METHODS
A retrospective analysis was performed on 180 patients with pancreatic carcinoma. Patients received one of seven regimens of chemotherapy. Unrelated to the type of chemotherapy, some patients received 1.25 mg warfarin daily. The primary end-point was median survival.


RESULTS
Treatment with warfarin resulted in improved median survival from the start of regional therapy (warfarin versus no warfarin: 5.0 versus 2.3 months, n = 111 versus 69; p < 0.0001). This effect was not dependent on the type of chemotherapy used. Among the seven regimens examined, the one consisting of regional gemcitabine and mitomycin-C with systemic gemcitabine was associated with the longest median survival of 5.1 months from the start of regional therapy (p = 0.006) and 12.7 months from diagnosis. This regimen combined with warfarin was associated with improved median survival (7.1 months, n = 32).


CONCLUSIONS
Treatment with low-dose warfarin improved survival irrespective of the chemotherapy received. Of the regimens examined, the combination of regional gemcitabine and mitomycin-C with systemic gemcitabine was associated with the longest survival time. Survival was increased further by the addition of warfarin. These data provide a rationale, based on safety and efficacy, for a definitive study on the use of warfarin and combined regional and systemic chemotherapy in patients with pancreatic carcinoma.
Nakchbandi
Wes
W
Department of Oncologic Surgery, Carl von Hess Hospital, Hammelburg, Germany.
Müller
Herwart
H
Singer
Manfred V
MV
Löhr
Matthias
M
Nakchbandi
Inaam A
IA
D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage* / Q000627:therapeutic use; D000925:Anticoagulants / Q000008:administration & dosage* / Q000627:therapeutic use; D002277:Carcinoma / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D007269:Injections, Intra-Arterial; D008297:Male; D008875:Middle Aged; D016685:Mitomycin / Q000008:administration & dosage / Q000627:therapeutic use; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D012189:Retrospective Studies; D012264:Ribonucleotide Reductases / Q000037:antagonists & inhibitors; D015996:Survival Rate; D016896:Treatment Outcome; D014859:Warfarin / Q000008:administration & dosage* / Q000627:therapeutic use; D000093542:Gemcitabine
D000903:Antibiotics, Antineoplastic; D000925:Anticoagulants; D007166:Immunosuppressive Agents; D003841:Deoxycytidine; D016685:Mitomycin; D014859:Warfarin; D012264:Ribonucleotide Reductases; D000093542:Gemcitabine